Payment overview · 2025
General Payments
$206.55
9 reported records · 5 companies
Healthcare provider profile · identity verified
Ashley Rollins, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1053700542
Verified facts
What the public records show
CMS Open Payments records show Ashley Rollins, MD received $206.55 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.96 | 39.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.59 | 21.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.70 | 19.2% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $22.03 | 10.7% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.27 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $206.55 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.59 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.70 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 64 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 502 | 147 |
| Levothyroxine Sodium | Levothyroxine Sodium | 432 | 125 |
| Lisinopril | Lisinopril | 299 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 88 |
| Losartan Potassium | Losartan Potassium | 263 | 74 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 220 | 74 |
| Omeprazole | Omeprazole | 215 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 62 |
| Gabapentin | Gabapentin | 159 | 46 |
| Metformin Hcl | Metformin Hcl | 149 | 49 |
| Simvastatin | Simvastatin | 141 | 43 |
| Montelukast Sodium | Montelukast Sodium | 134 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 115 | 35 |
| Buspirone Hcl | Buspirone Hcl | 114 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 34 |
| Trazodone Hcl | Trazodone Hcl | 108 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 105 | 56 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 28 |
| Sertraline Hcl | Sertraline Hcl | 99 | 29 |
| Carvedilol | Carvedilol | 93 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 26 |
| Alprazolam | Alprazolam | 90 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 90 | 23 |
| Glipizide Er | Glipizide | 86 | 22 |
| Meloxicam | Meloxicam | 85 | 26 |
| Bupropion Xl | Bupropion Hcl | 84 | 23 |
| Cefdinir | Cefdinir | 81 | 75 |
| Metformin Hcl Er | Metformin Hcl | 80 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 26 |
| Tramadol Hcl | Tramadol Hcl | 74 | 19 |
| Alendronate Sodium | Alendronate Sodium | 71 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 69 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 43 |
| Furosemide | Furosemide | 68 | 27 |
| Azelastine Hcl | Azelastine Hcl | 64 | 25 |
| Ozempic | Semaglutide | 64 | 15 |
| Methylprednisolone | Methylprednisolone | 63 | 52 |
| Synthroid | Levothyroxine Sodium | 62 | 21 |
| Famotidine | Famotidine | 59 | 24 |
| Allopurinol | Allopurinol | 58 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | 11 |
| Januvia | Sitagliptin Phosphate | 54 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 17 |
| Azithromycin | Azithromycin | 51 | 44 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 49 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 44 | 14 |
| Clonazepam | Clonazepam | 43 | suppressed |
| Ezetimibe | Ezetimibe | 41 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 41 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | 11 |
| Fluconazole | Fluconazole | 40 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 14 |
| Mupirocin | Mupirocin | 38 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | 12 |
| Donepezil Hcl | Donepezil Hcl | 37 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | 13 |
| Bumetanide | Bumetanide | 35 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | 11 |
| Glipizide | Glipizide | 34 | suppressed |
| Lansoprazole | Lansoprazole | 34 | 11 |
| Meclizine Hcl | Meclizine Hcl | 34 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | suppressed |
| Potassium Chloride | Potassium Chloride | 32 | suppressed |
| Valsartan | Valsartan | 32 | 11 |
| Eliquis | Apixaban | 31 | 12 |
| Glimepiride | Glimepiride | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | 13 |
| Valacyclovir | Valacyclovir Hcl | 25 | 21 |
| Acyclovir | Acyclovir | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 22 | 22 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 18 |
| Amoxicillin | Amoxicillin | 21 | 19 |
| Levofloxacin | Levofloxacin | 21 | 18 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Estradiol | Estradiol | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Prednisone | Prednisone | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $206.55 · 9 records | Novo Nordisk Inc | FREESTYLE LIBRE 3, OTEZLA, Ozempic, REPATHA, Rybelsus, VRAYLAR, Veozah | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error